|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 71.42 EUR | -0.94% |
|
+7.37% | +4.08% |
| 06-05 | Milan stock market opens flat ahead of US data; profit-taking hits Diasorin and STM, Erg rallies | RE |
| 06-05 | European markets set for mixed open following Dow record | AN |
Business description: DiaSorin S.p.A.
At the end of 2025, the group had 9 production sites located in Italy, the United States (4), Canada, Germany, the United Kingdom and Chine.
Net sales are distributed geographically as follows: Italy (15.2%), Europe (24.9%), North America (51.8%), and other (8.1%).
Number of employees: 3,242
Sales by Activity: DiaSorin S.p.A.
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
Sale of Diagnostic Kits | 1.24B | 1.36B | 1.15B | 1.19B | 1.2B |
Geographical breakdown of sales: DiaSorin S.p.A.
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
North America | 765M | 938M | 722M | 750M | 751M |
Italy | 583M | 511M | 446M | 491M | 497M |
Europe | 303M | 288M | 284M | 309M | 318M |
Rest of The World | 120M | 112M | 102M | 102M | 96.86M |
Eliminations | -533M | -487M | -406M | -467M | -468M |
Executive Committee: DiaSorin S.p.A.
| Manager | Title | Age | Since |
|---|---|---|---|
Carlo Rosa
CEO | Chief Executive Officer | 60 | 25/03/2007 |
Alberto Donati
DFI | Director of Finance/CFO | - | 31/12/2024 |
Luigi Cicchese
CTO | Chief Tech/Sci/R&D Officer | - | - |
Rita Maffei
CTO | Chief Tech/Sci/R&D Officer | - | - |
Fabrizio Bonelli
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/2018 |
Composition of the Board of Directors: DiaSorin S.p.A.
| Director | Title | Age | Since |
|---|---|---|---|
Carlo Rosa
BRD | Director/Board Member | 60 | 27/04/2016 |
| Director/Board Member | 63 | 25/03/2007 | |
Michele Denegri
CHM | Chairman | 57 | 28/04/2022 |
Roberta Somati
BRD | Director/Board Member | 57 | 21/04/2013 |
Stefano Altara
BRD | Director/Board Member | 59 | 22/04/2014 |
| Director/Board Member | 86 | 27/04/2016 | |
Monica Tardivo
BRD | Director/Board Member | 56 | 27/04/2016 |
Diego Pistone
BRD | Director/Board Member | 75 | 28/04/2022 |
| Director/Board Member | 56 | 28/04/2022 | |
Fioranna Negri
BRD | Director/Board Member | 68 | 27/04/2025 |
Holdings: DiaSorin S.p.A.
| Name | Equities | % | Valuation |
|---|---|---|---|
DIASORIN S.P.A. 3.34% | 1,868,672 | 3.34% | 127 M $ |
Company details: DiaSorin S.p.A.
Group companies: DiaSorin S.p.A.
| Name | Category and Sector |
|---|---|
Diasorin, Inc.
 Diasorin, Inc. Medical SpecialtiesHealth Technology Develops and manufactures reagents for in vitro diagnostics |
Medical Specialties
|
Diasorin, Inc.
Diasorin, Inc. Medical SpecialtiesHealth Technology Develops and manufactures reagents for in vitro diagnostics |
Medical Specialties
|
Luminex Molecular Diagnostics, Inc.
 Luminex Molecular Diagnostics, Inc. Medical/Nursing ServicesHealth Services Develops DNA-based diagnostics tests and software solutions |
Medical/Nursing Services
|
Diasorin Italia SpA
 Diasorin Italia SpA Medical/Nursing ServicesHealth Services Provides immunodiagnostics and molecular diagnostics services |
Medical/Nursing Services
|
Diagnostic & Testing Substances
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.94% | +7.37% | -21.57% | -26.37% | 4.37B | |
| -5.60% | -3.15% | +159.47% | +287.80% | 16.66B | |
| -0.75% | -2.02% | -39.54% | -22.42% | 9.92B | |
| -1.79% | +1.69% | +25.71% | +15.27% | 6.57B | |
| +2.28% | -4.84% | -27.78% | -25.14% | 5.16B | |
| -4.57% | -1.38% | - | - | 4.66B | |
| -4.38% | -7.35% | +87.73% | +78.04% | 4.37B | |
| -7.34% | +9.66% | +240.72% | -43.54% | 3.94B | |
| +1.70% | -7.22% | -19.33% | -44.17% | 2.62B | |
| -0.93% | -2.78% | -38.91% | -57.49% | 1.38B | |
| Average | -2.23% | -0.75% | +40.72% | +18.00% | 5.96B | |
| Weighted average by Cap. | -2.87% | -1.22% | +62.24% | +80.03% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- DIA Stock
- Company DiaSorin S.p.A.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition